In vivo, this may be secondary to low tumor mutational burden and lack of neoantigen recognition, the loss of beta-2-microglobulin (β2m), or loss of major histocompatibility complex (MHC) I. β2m is a component of HLA class 1 molecules, and loss of expression prevents antigen presentation [4]. Here, B2M is linked to neoplasm.